STUDresearch · Peptide

Pemvidutide

Also known as

ALT-801 · Pemvidutide (Altimmune) · GLP-1/glucagon dual agonist · GLP-1R/GCGR dual agonist · Balanced 1:1 GLP-1/glucagon coagonist · EuPort GLP-1/glucagon dual agonist

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗

Peptide Some talk Systemic SubQ Metabolic / GLP-1 class

Systemic once-weekly dual GLP-1/glucagon agonist — whole-body appetite, weight, cardiometabolic, and liver-fat effects rather than a local tissue inject.

What people say Pemvidutide (ALT-801) is an investigational GLP-1/glucagon dual agonist discussed for weight loss and liver disease. It is not a GIP triple agonist or a finished consumer product; obesity and MASH results describe different trial populations. Doses people talk about

Obesity trial arms1.2 / 1.8 / 2.4 mg weekly SC

MOMENTUM followed these arms for 48 weeks. The 2.4 mg mean-weight result is a trial endpoint, not a preferred personal dose.

MASH trial arms1.2 / 1.8 mg weekly SC

The IMPACT population and liver-biopsy endpoints differ from the obesity study. Lower GI discontinuation figures there do not erase the obesity-program burden.

Earlier liver-fat studies1.2 / 1.8 / 2.4 mg weekly SC

Twelve-week studies could extend to 24 weeks; the number of weeks is a study course, not the drug’s half-life.

Early Phase 1 used weekly SC exposure without titration. Later MOMENTUM notes distinguish lower full-start arms from a short ramp for 2.4 mg; neither design is a DIY escalation plan.

Half-life & effect duration

Half-life in the body: Sponsor table · injectedAbout 110 hours
Secondary estimateAbout 144 hours — roughly 6 days
Felt duration people report: Felt durationNo consistent pemvidutide-specific firsthand window reported

Timing context & sources

How it may feel Appetite reduction and GI effects shape the discussion, but direct pemvidutide diaries remain sparse. Opened community threads debate trial tolerability; their personal treatment stories are about other incretins. Nausea, vomiting and bowel changes are reported in pemvidutide trials.

Cycles people discuss This is discussed as sustained treatment, not a short gym cycle: 12–24-week liver-fat studies, 24-week endpoints and 48-week obesity programs appear in the record. A fixed community on/off course or safe restart schedule is not established. Timing Trials use once-weekly SC dosing. The 1.2 and 1.8 mg arms generally started at full dose, while 2.4 mg ramped over about four weeks; study courses ran 12–48 weeks depending on indication. This is trial timing, not a self-directed ladder. Stacks Trial monotherapy with diet/activity is distinct from online comparisons with other incretins. Multi-incretin combinations are unvalidated and can compound GI and nutritional problems; protein and resistance-training talk does not establish a drug stack. Watch for Not risk-free: Strong weight and liver signals sit next to real GI burden at higher doses, open long-term safety, and zero purity guarantee outside trials.

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

Sponsor table: 110-hour half-life at 1.8 mg SC.

The table also lists Tmax of 70 hours in the Phase 1 presentation.

Sponsor disclosure rather than a complete peer-reviewed PK analysis; the older 144-hour secondary figure remains unverified. This is not felt duration.

Altimmune corporate presentation: pemvidutide PK table (opens in a new tab)PDF page 18 (zero-based page 17), “PEMVIDUTIDE PK PROFILE CONFIRMS WEEKLY DOSING”: ALT-801 1.8 mg SC column; 110-hour half-life and 70-hour Tmax. Surrounding Phase 1 MAD trial and safety slides inspected as extracted text.Sponsor-authored presentation on a third-party mirror, not a peer-reviewed PK table. Table text reviewed; screenshot requests did not expose an image for visual inspection. Single table column does not establish all-dose or individualized timing.
Altimmune 2021 Phase 1 MAD results (opens in a new tab)2021-09-28 release: study design paragraphs; 12-week MAD weight-loss and safety tables; discussion immediately following safety table.Sponsor summary of 34 non-diabetic overweight/obese volunteers receiving 1.2, 1.8 or 2.4 mg SC weekly without titration. Not the later MOMENTUM design, MASH population or a first-person diary.

Felt duration people report

A pemvidutide-specific appetite or GI onset-to-offset interval is not established here.

The visible community discussions focus on trial interpretation and future expectations. Their first-person experiences involve other incretins.

No verified pemvidutide diary or same-author treatment follow-up was identified in these two threads; trial weight endpoints cannot substitute.

Has anyone heard or tried pemvidutide? (opens in a new tab)Opening question and all visible substantive replies, especially LoosedOfLimits on prior tirzepatide use and steven_meyerr on trial-population/durability limits.No pemvidutide treatment log in the visible discussion. Reported liver-lab improvement was with tirzepatide; stock ownership and hypothetical liver targeting are not evidence of pemvidutide experience or distribution.
Pemvutitide Superior Tolerability: debate and follow-up (opens in a new tab)Opening post; drewstrong83 and possible-penguin personal experiences; GoreBurnelli8105 reply on the 2.4 mg arm; Excellent-Ad-9925 explanation and Local-Law-1461 correction follow-up.Investor discussion with competing interpretations of trial design. Actual personal treatment experiences concern Wegovy/Mounjaro, not pemvidutide. No reported pemvidutide onset/offset or verified dosing diary.

What people say 18

Community rank: Grouped with survodutide / mazdutide / retatrutide when people map “glucagon-containing” fat + liver dual/triple talk; often framed as biotech pipeline, not daily research-chem staple. forum
Appetite: Class-default less hunger / easier deficit once on effective weekly dose. forum
Weight loss MOMENTUM Phase 2 obesity (48 weeks, n≈391, no diabetes, diet+exercise adjunct): Mean losses ~10.3% (1.2 mg), ~11.2% (1.8 mg), ~15.6% (2.4 mg) vs ~2.2% placebo (MMRM). trial
High-dose responders (MOMENTUM 2.4 mg, completer-style responder tables): >50% hit ≥15% loss; ~32% hit ≥20% at 48 weeks; ≥5% / ≥10% rates also strongly dose-favoring drug vs placebo. trial
Near-linear late curve: 2.4 mg trajectory still declining near end of 48 weeks — company narrative of potential further loss with continued treatment. trial
Week-24 interim MOMENTUM: ~7.3% / 9.4% / 10.7% at 1.2 / 1.8 / 2.4 mg vs ~1.0% placebo; higher relative efficacy in subjects ≤115 kg baseline. trial
Body composition (MOMENTUM MRI substudy, n=50 on drug, ADA 2024): ~78.1% of lost weight as fat mass / ~21.9% as lean — company “class-leading lean preservation” vs historical reports of up to ~40% lean share on other incretins; cross-trial comparisons are not head-to-head. trial
Liver fat MASLD/NAFLD Phase 2 (12–24 weeks): Large MRI-PDFF relative LFC drops — public figures include up to ~68.5% relative reduction at 12 weeks and ~56–76% relative reductions at 24 weeks by dose band vs low double-digit or single-digit placebo. trial
Liver normalization / responders: High rates of ≥30% relative LFC drop and meaningful LFC normalization vs placebo in NAFLD cohorts; cT1 (fibro-inflammation MRI proxy) responder rates far above placebo. trial
Liver enzymes: ALT reductions and related hepatic inflammation markers improved vs placebo in MASLD and MASH programs. trial
IMPACT Phase 2b MASH (24 weeks, F2/F3 biopsy, 1.2 / 1.8 mg): Primary MASH resolution without fibrosis worsening met — ITT-style reports ~59% / ~52% on 1.2 / 1.8 mg vs ~19% placebo; fibrosis-improvement-without-MASH-worsening arm not statistically significant at 24 weeks. trial
IMPACT 48-week NITs: Continued liver-fat reductions (~45% / ~55% mean relative at 1.2 / 1.8 mg vs ~8% placebo in company 48-week summaries); ELF + LSM dual-response and fibrosis-biomarker talk; additional weight loss on 1.8 mg without clear plateau. trial
Weight in MASH context: IMPACT 24-week means ~5.0% / ~6.2% at 1.2 / 1.8 mg vs ~1.0% placebo — meaningful but lower than MOMENTUM 2.4 mg obesity means (different population/dose set). trial
Lipids (MOMENTUM): Triglycerides down sharply (e.g. ~−35% at 2.4 mg LSM vs rise on placebo); total cholesterol and LDL also improved in secondary tables. trial
Blood pressure / heart rate: Systolic/diastolic BP improved or stable-favorable vs placebo; heart-rate change small (roughly low single-digit bpm LSM at higher doses) without MACE signal in MOMENTUM summaries. trial
Glucose homeostasis (obesity trials): Fasting glucose and HbA1c largely steady — not positioned as a pure T2D incretin story; Phase 1b T2D safety work reported weight loss with limited HbA1c punch vs classic diabetes agents. trial
RECLAIM Phase 2 AUD (2.4 mg weekly × 24 weeks, overweight/obese AUD): Primary endpoint met — least-squares mean ~1.45 fewer heavy drinking days/week vs placebo; company also reported meeting key secondary WHO risk-drinking-level endpoints. trial
Absolute loss framing (company 2.4 mg): ~15.6% mean framed as ~32 lb mean loss at 48 weeks in press materials (baseline-dependent; mean baseline ~104 kg / BMI ~37). trial

Doses people talk about 11

Community / research-chem reality: Authentic personal mg charts and vial math are rare vs retatrutide or tirzepatide gray-market culture; unlabeled “GLP-1/glucagon dual” research products are not verified as clinical pemvidutide. forum
Do not invent ladders: Unlike reta (2→4→8→12 mg lore) or tirz (2.5→15 mg), there is no widely shared multi-step “bro ladder” beyond the trial full-start / short 2.4 mg ramp pattern. forum
Framing: Published/trial and community discussion ranges only — research/educational context, not medical advice, not approved labeling, not a gray-market protocol endorsement. forum
Obesity / MOMENTUM weekly arms: Once-weekly subQ 1.2 mg, 1.8 mg, 2.4 mg for 48 weeks with diet + activity. trial
Titration culture (trial): 1.2 mg and 1.8 mg typically started at full dose; 2.4 mg used a short titration over about the first 4 weeks. No multi-month 8–20 week ladder like sema/tirz/reta public ladders. trial
Efficacy band most cited: 2.4 mg weekly for peak obesity mean loss (~15.6% at 48 weeks MOMENTUM). trial
MASH / IMPACT doses: 1.2 mg and 1.8 mg once weekly (2.4 mg not the IMPACT pair); biopsy primary at 24 weeks with extension NITs to 48 weeks. trial
AUD RECLAIM dose: 2.4 mg once weekly × ~24 weeks vs placebo (≈100 participants, BMI >25). trial
MASLD/NAFLD Phase 2 doses: Same 1.2 / 1.8 / 2.4 mg weekly bands as obesity, 12 weeks with optional extension to 24 weeks in earlier designs. trial
Phase 3 PERFORMA (MASH): Global registrational program initiated/enrolling in 2026 company announcements — dose set and titration details should be taken from protocol/registry, not assumed identical to Phase 2. trial
Lifestyle co-intervention: MOMENTUM obesity arms included reduced-calorie diet + increased activity; some MASLD work emphasized pharmacology with less lifestyle co-prescription — context matters when comparing % losses. trial

How it may feel 8

Multi-month plateau talk: Sparse molecule-specific personal logs; community borrows general incretin advice (protein, resistance training, GI management, dose hold) rather than pemvidutide-unique schedules. In two opened Reddit discussions, people debate liver and GI trial results, but the personal treatment stories concern tirzepatide, Wegovy or Mounjaro. They do not establish pemvidutide’s felt onset, duration or plateau timing. forum
Weeks 0–4 (onboarding): 1.2 and 1.8 mg often full-start in trials; 2.4 mg uses a short ~4-week ramp. Early GI (nausea, vomiting, bowel change) clusters here even without long multi-month titration. trial
Weeks 1–4 GI reality: Company narrative stresses “no long titration needed” via EuPort slow absorption — still, higher MOMENTUM doses saw substantial nausea rates; full-start is not side-effect-free. trial
Weeks 4–12: Early weight separation and (in liver trials) rapid LFC drops; appetite settling if the dose is held is a discussion expectation, not a measured universal trajectory. Most drug-related discontinuations in MOMENTUM clustered in first ~16 weeks. trial
Weeks 12–24: Further weight and liver-fat separation from placebo; IMPACT biopsy endpoint window; RECLAIM AUD heavy-drinking endpoint at 24 weeks. trial
Weeks 24–48 (obesity): MOMENTUM high dose kept a near-linear loss path; body-composition story (fat-preferential) is a 48-week MRI narrative. trial
Weeks 24–48 (MASH IMPACT): NITs, lipids, weight, and BP improvements tracked out to a year in company EASL-era updates; 1.8 mg weight still moving without clear plateau talk. trial
If GI limits: Trial protocols often did not allow dose reduction for intolerance (unlike some peer incretin designs) — real-world discussion therefore stresses slower start, smaller meals, or not pushing 2.4 mg. trial

Cycles people discuss 7

Community “runs”: Sparse molecule-specific logs; when discussed, people borrow multi-month incretin patterns (stay on until goal/intolerance/supply) rather than timed on/off peaking cycles. forum
Off periods: No standard pemvidutide off-cycle, PCT, or bridging protocol in community literature; post-stop weight and appetite maintenance remain open class problems. forum
Not a short recomp stack: Discussed as systemic metabolic agonist, not a 4–6 week injury or cosmetic peptide course. forum
Obesity trial length: MOMENTUM 48 weeks continuous weekly dosing — development model is chronic use, not 8–12 week bodybuilding cycles. trial
Liver fat / MASLD lengths: ~12–24 weeks in earlier NAFLD programs; IMPACT MASH 24-week biopsy primary with 48-week NIT follow-through. trial
AUD trial length: RECLAIM ~24 weeks weekly. trial
Phase 3 horizon: PERFORMA MASH Phase 3 is long registrational (multi-year outcome/fibrosis windows in public planning talk) — continuous weekly therapy model. trial

Timing 9

Practical timing: Same weekday weekly; meal timing micromanagement less standardized than daily orals. Missed-dose handling is clinical-protocol territory, not a mature forum FAQ. forum
Washout versus felt effect: Multi-week residual exposure is an expectation extrapolated from a multi-day plasma clock, not a measured duration of appetite control, nausea or protection. Exact personal clearance and felt offset are not established by the opened table. forum
Weekly design intent: EuPort domain extends half-life and is described as slowing entry into blood — supports once-weekly subQ and is the company’s GI-tolerability differentiator claim. trial
Human PK table versus secondary shorthand: The opened sponsor table for ALT-801 1.8 mg SC reports a 110-hour half-life and 70-hour time to peak concentration. Older secondary summaries cite ≈144 hours / ~6 days; that figure is retained as unverified shorthand, not a pooled measured range or an inherited incretin-class value. trial
Albumin binding: Fatty-acid / EuPort albumin-binding strategy reduces renal clearance and proteolysis (preclinical and mechanism decks describe very high albumin association). trial
Cadence: Fixed once-weekly injection day — not daily microdosing and not multi-day split dosing in public trial designs. trial
Peak vs trough GI theory: Company and publications argue GI AEs track peak concentration; flatter absorption curve is the rationale for full-start lower doses. trial
Glucagon downstream: Hepatic fat oxidation, energy-expenditure, and lipid-mobilization narratives beyond pure GLP-1 appetite suppression — the “diet + exercise mimetic” marketing line. trial
GLP-1 downstream: Satiety, gastric emptying slowdown, and class metabolic effects. trial

Stacks 7

Standalone metabolic agonist: Discussed as solo weekly dual agonist for fat/liver goals — not a BPC-157 / TB-500 injury stack component. forum
Compare, don’t combine incretins: Community comparison set is usually semaglutide, tirzepatide, survodutide, retatrutide, mazdutide — not concurrent stacking of multiple GLP-1-pathway agents. forum
Multi-incretin risk: Stacking pemvidutide-class duals with sema/tirz/reta treated as high-risk receptor redundancy and GI/gallbladder load — generally discouraged in cautious discussion. forum
Support tactics (class): Higher protein targets, lifting to defend lean mass, anti-nausea strategies (meal size, timing, OTC talk), fiber/electrolytes for bowel swings — adjunct habits, not proven pemvidutide-specific stacks. forum
Liver-angle pairing talk: Sometimes discussed alongside other MASH pipeline agents in strategy threads, but combination regimens are clinical-trial territory, not established DIY stacks. forum
No standard GLOW/Wolverine-style ratio blend: Not a multi-peptide pre-mix culture compound. forum
Trial lifestyle stack: Calorie reduction + increased physical activity co-prescribed in MOMENTUM obesity; protein + resistance training emphasized in body-composition preservation talk. trial

Storage notes 2

No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Related 8

Watch for 16

Class risks (imported caution discourse): Gallbladder events, pancreatitis discussion, muscle/lean loss if protein and training are neglected, nutrient gaps with rapid loss, dehydration with vomiting/diarrhea. forum
Borrowed boxed-warning style talk: Medullary thyroid carcinoma / MEN2-style GLP-1 class cautions are often imported in community risk lists — class discourse, not a finished pemvidutide consumer label. forum
Counterfeit / research-chem risk: Non-trial powders easily mislabeled or contaminated; dual-agonist labels are especially hard to verify analytically for end users. forum
GI AEs (dominant class): Nausea, vomiting, diarrhea, constipation — top adverse-event category across programs; predominantly mild–moderate in company summaries. trial
MOMENTUM nausea rates (approx.): Placebo ~11%; 1.2 mg ~26%; 1.8 mg ~60%; 2.4 mg ~52% — full-start higher doses still GI-heavy. trial
MOMENTUM vomiting: Placebo ~3%; 1.2 mg ~6%; 1.8 / 2.4 mg ~27–28%. trial
MOMENTUM diarrhea / constipation: Dose-related rises (diarrhea up to ~19% at 2.4 mg; constipation up to ~23% at 2.4 mg in tabulated summaries). trial
Discontinuations (MOMENTUM): AEs leading to stop ~5% / ~19% / ~20% at 1.2 / 1.8 / 2.4 mg vs ~6% placebo; drug-related discontinuations ~4% / ~16% / ~16% vs ~2% placebo — higher doses are not “side-effect free” despite EuPort marketing. trial
IMPACT MASH tolerability contrast: Very low AE-related discontinuations reported (~0% / ~1% at 1.2 / 1.8 mg vs low single-digit placebo) in 24-week toplines — different population and dose set than MOMENTUM 2.4 mg obesity. trial
Serious AE example: Rare drug-related SAEs of severe vomiting / rehydration reported at 2.4 mg in obesity program materials. trial
Cardiac narrative: MOMENTUM emphasized no MACE imbalance, low arrhythmia rates, and only small HR LSM changes — still investigational long-term CV outcomes data. trial
Full-start still hits GI: Short/no long titration is a differentiator claim, not a guarantee of zero nausea or bowel issues. trial
Investigational status: Outside supervised trials there is no approved indication, no verified pharmacy product identity, and no long-term safety label. trial
Glucose / T2D nuance: Obesity trials kept glucose fairly flat; do not assume diabetes-drug-level glycemic rescue or identical T2D side-effect profile. trial
Alcohol / AUD context: RECLAIM GI rates (nausea etc.) still present; drinking-reduction signals do not make unsupervised use appropriate for AUD treatment. trial
Not risk-free: Strong weight and liver signals sit next to real GI burden at higher doses, open long-term safety, and zero purity guarantee outside trials. trial

Updated: 2026-08-12

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.

↑ Back to top

Half-life & effect duration

Timing context & sources⌄

Half-life in the body

Felt duration people report

What people say 18

Doses people talk about 11

How it may feel 8

Cycles people discuss 7

Timing 9

More on what it is 8

Stacks 7

Storage notes 2

Related 8

Watch for 16

Timing context & sources